ClinicalTrials.gg
RecruitingNCT07832292Updated Nov 3, 2026

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

A Phase 2 interventional study of JNJ-101556143 in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Recruiting at 14 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 3, 2026Now RecruitingFirst sites in 4 new countries+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.

Planned enrollment
32nd of 68
100 · median 82
Started
2026
with 3 others
Phase 2
20 of 88
1 open now
Primary completion
2029-05
later than 21 of 22 live
Registered
87th of 88
by date

Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 32nd largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 21 of the 22 other live ones, and was the 87th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Prostatic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tumor, mixed neuroendocrine carcinoma, large cell neuroendocrine carcinoma, or sarcoma of the prostate is disallowed
  • Progressive androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level greater than or equal (>=) 10 nanograms per milliliter (ng/mL) and at least one of the following: (a) PSA progression defined as at least 2 consecutive increases in PSA value over a previous reference value measured at least 1 week apart. (b) Progressive disease or new lesion(s) in the lymph nodes, bones, or viscera on conventional imaging (computed tomography [CT]/magnetic resonance imaging [MRI]) as defined by version 1.1 (RECIST v1.1) and/or on bone scan per Prostate Cancer Working Group 4 (PCWG4) while on Androgen Deprivation Therapy (ADT) (either surgically [bilateral orchiectomy] or with medication). Local-regional disease including invasive disease of rectum, bladder, pelvis is allowed as long as participant has a current or past history of distant metastasis (M1 disease). Participants in Part 1 must have per RECIST v1.1 by conventional imaging with CT or MRI (chest, abdomen, and pelvis) and/or Technetium-99\^m (99\^mTc) bone scan confirmed by Blinded Independent Central Review (BICR) at the time of screening
  • Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog [agonist or antagonist]) with castrate level of serum testosterone (less than [\<] 50 nanograms per deciliter [ng/dL] or 1.7 nanomoles per liter [nmol/L]) prior to the first dose of trial intervention and must continue this therapy throughout the treatment phase
  • Have discontinued concurrent use of any non- systemic anticancer therapy (that is, cytotoxic chemotherapy, Androgen Receptor Pathway Inhibitor (ARPI), radiation therapy) within 2 weeks or Lutetium-177 Prostate-Specific Membrane Antigen-617 (177\^Lu PSMA-617) within 6 weeks prior to first dose of trial intervention, or any investigational drugs within 3 months of first dose of trial intervention
  • Toxicity related to prior anticancer treatment that is deemed must have resolved to (CTCAE) Version 6.0 Grade 1 or better

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver , or stable chronic liver disease per investigator assessment)
  • Suspected or known allergies, , or intolerance to JNJ-101556143 or its
  • Had major surgery or had significant traumatic injury less than or equal to 28 days of the first dose of trial intervention. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate
  • Spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
  • Solid organ or bone marrow transplantation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    JNJ-101556143

    Participants will receive JNJ-101556143 orally once daily in a 28-day treatment cycle until confirmed radiographic progression by blinded independent central review (BICR) or unequivocal clinical progression, or any other protocol-defined discontinuation criteria is met.

    Drug: JNJ-101556143

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Confirmed overall response, is defined as having either confirmed complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) prior to any subsequent anti-cancer therapy.

    Time frame: Up to 2 years and 8 months

Secondary outcomes

  1. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response for a confirmed radiographic response (CR or PR) per RECIST v1.1 until the date of documented radiographic progression by BICR, or death, whichever comes first.

    Time frame: Up to 2 years and 8 months

  2. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from the date of initiation of therapy until the date of radiographic disease progression or death, whichever comes first.

    Time frame: Up to 2 years and 8 months

  3. Time to Symptomatic Progression (TSP)

    TSP is defined as the time from the first dose of trial intervention until the date of symptomatic progression or death, whichever comes first.

    Time frame: Up to 2 years and 8 months

  4. Number of Participants with Treatment-Emergent Adverse Event (TEAE) by Severity

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale defined as Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 2 years and 8 months

  5. Number of Participants with Abnormalities in Clinical Laboratory Tests

    Number of participants with abnormalities in clinical laboratory tests will be reported.

    Time frame: Up to 2 years and 8 months

  6. Minimum Plasma Concentration (Cmin) of JNJ-101556143

    Minimum plasma concentration of JNJ-101556143 will be reported.

    Time frame: Pre-dose (0 hours); 2 to 3 hours post dose from Cycle 1 to Cycle 2 and 4 to 8 hours post dose from Cycle 1 to Cycle 2 (Each Cycle Duration= 28 days)

  7. Maximum Plasma Concentration (Cmax) of JNJ-101556143

    Maximum plasma concentration of JNJ-101556143 will be reported.

    Time frame: Pre-dose (0 hours); 2 to 3 hours post dose from Cycle 1 to Cycle 2 and 4 to 8 hours post dose from Cycle 1 to Cycle 2 (Each Cycle Duration= 28 days)

  8. Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24h) of JNJ-101556143

    AUC0-24h is the area under the plasma concentration-time curve from the time of JNJ-101556143 dose administration up to 24-hour dosing interval.

    Time frame: Pre-dose (0 hours); 2 to 3 hours post dose from Cycle 1 to Cycle 2 and 4 to 8 hours post dose from Cycle 1 to Cycle 2 (Each Cycle Duration= 28 days)

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 32 months is close to that.

Counting every sponsor, half of 726 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 21, 2026
StartActual
Sep 16, 2026
Primary completionEst.
May 17, 2029
CompletionEst.
May 20, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
14 sites added — first sites in China, United States, Australia and Japan
Show 14 added (7 United States, 4 Australia, 2 China, 1 Japan)
  • Southern Urology LLC · Lafayette, United States
  • Greater Boston Urology · Plymouth, United States
  • Associated Medical Professionals · Syracuse, United States
  • The Conrad Pearson Clinic · Germantown, United States
  • Sun Yat Sen University Cancer Center · Guangzhou, China
  • Advanced Urology Institute · Largo, United States
  • Associated Urological Specialists · Chicago Ridge, United States
  • Urology of Indiana · Carmel, United States
  • Icon Ctr Chermside · Chermside, Australia
  • Epworth Healthcare · East Melbourne, Australia
  • Icon Cancer Ctr Hobart · Hobart, Australia
  • Icon Cancer Centre Kurralta Park · Kurralta Park, Australia
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
  • Kobe University Hospital · Kobe, Japan
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Start date
Sep 28, 2026→Sep 16, 2026 (actual)
Sep 25, 2026
Show all 2 updates
  1. Nov 3, 2026
    9 sites added — first sites in Australia and Japan
    Show 9 added (4 Australia, 3 United States, 1 China, 1 Japan)
    • Advanced Urology Institute · Largo, United States
    • Associated Urological Specialists · Chicago Ridge, United States
    • Urology of Indiana · Carmel, United States
    • Icon Ctr Chermside · Chermside, Australia
    • Epworth Healthcare · East Melbourne, Australia
    • Icon Cancer Ctr Hobart · Hobart, Australia
    • Icon Cancer Centre Kurralta Park · Kurralta Park, Australia
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    • Kobe University Hospital · Kobe, Japan
    + 1 other change: verification date
  2. Sep 25, 2026
    Not yet recruiting→Recruiting
    5 sites added — first sites in China and United States
    Show 5 added (4 United States, 1 China)
    • Southern Urology LLC · Lafayette, United States
    • Greater Boston Urology · Plymouth, United States
    • Associated Medical Professionals · Syracuse, United States
    • The Conrad Pearson Clinic · Germantown, United States
    • Sun Yat Sen University Cancer Center · Guangzhou, China
    Start date Sep 28, 2026→Sep 16, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07832292
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Sep 16, 2026
Primary completion
May 17, 2029 (estimated)
Completion
May 20, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915

Start the discussion